Canaccord lowered the firm’s price target on Theratechnologies to $5 from $8 and keeps a Hold rating on the shares. The firm updated their model to reflect 2023 results, increasing commercial growth rates, offset by spend needed to advance the sales effort. Further, they are moderating expectations on sudocetaxel zendusortide.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on THTX:
- Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2023 and Provides 2024 Guidance
- Theratechnologies reports Q4 revenue $23.45M, consensus $23.36M
- Theratechnologies announces publication in Frontiers in Immunology on TH1902
- Theratechnologies Announces Publication in Frontiers in Immunology that Deepens Understanding of Sudocetaxel Zendusortide (TH1902) Molecular Mechanism of Action
- THTX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
